Class Action Lawsuit Adds Legal Risk to Microvast's Precarious Position

What happened

Microvast faces a securities class action lawsuit covering purchasers from April 1, 2025 to March 16, 2026, compounding existing going-concern doubt after Q1-2026 revenue plunged 48% and operating cash burn reached $22.8 million. The lawsuit introduces significant legal overhang on top of the company's primary near-term catalyst—resolving the $76.5 million related-party convertible loan maturing May 28, 2026—now under increased uncertainty. Management's ability to navigate its liquidity crunch and operational turnaround is further distracted by potential legal costs, settlement demands, and reputational damage. The class period coincides with elevated stock prices, implying potentially material damages if the suit succeeds. This development reduces the probability of a clean turnaround and increases the likelihood of substantial dilution or restructuring.

Implication

Investors should treat the class action lawsuit as a material negative catalyst that amplifies existing risks. The going-concern warning, revenue collapse, and dependence on the May 2026 convertible loan were already concerning; now legal liability adds another cash drain and management distraction. Until the company provides clarity on both its refinancing plan and the lawsuit's potential impact, the stock remains highly speculative. The most likely scenarios involve substantial dilution or a distressed outcome, both destructive to equity. We recommend avoiding or reducing exposure given the low probability of a favorable near-term resolution.

Thesis delta

The addition of a securities class action lawsuit transforms the risk profile from primarily operational/financing to include significant legal overhang. Our previous base case assumed a 45% probability of normalizing shipments and resolving the convertible; now we see a higher probability (50%+) of an adverse outcome that includes punitive legal costs or forced equity issuance. The timeline for resolution extends, and the 'wait and see' approach now incorporates an additional negative catalyst that could emerge at any time.